Abstract. Subclinical hypothyroidism (SCH) is becoming a global health problem due to its increasing prevalence and potential adverse effects, including cardiovascular diseases and nonalcoholic fatty liver disease (NAFLD). However, the association between SCH and NAFLD remains controversial. MicroRNAs (miRNAs/miRs) have been reported to be implicated in lipid metabolism disorders; however, how miRNAs regulate hepatic lipid metabolism in SCH mice remains unknown. The present study investigated miRNA alterations and proteome profiles in an SCH mouse model, which was generated by methimazole administration in mice for 16 weeks. Next, the profiles of 17 miRNAs that are critical to hepatic lipid metabolism and the proteome were investigated using reverse transcription-quantitative polymerase chain reaction and iTRAQ labeling in the liver specimens of SCH (n=9) and control (n=7) mice. Putative target prediction of miRNAs was also conducted using TargetScan and miRanda. Compared with the control mice, SCH mice had 8 miRNAs and 36 proteins with significantly different expression in the liver tissues. Furthermore, a regulatory module containing 3 miRNAs (miR-34a-5p, miR-24-3p and miR-130a-3p) and 4 proteins (thioredoxin, selenium-binding protein 2, elongation factor 1β and prosaposin) was identified. Overall, integrated analysis of miRNAs and the proteome highlighted a regulatory module between miRNAs and proteins, which, to a certain extent, may contribute to a better understanding of hepatic lipid metabolism disorders in SCH mice.

Introduction

Subclinical hypothyroidism (SCH) is closely associated with disturbances in lipid metabolism, and is characterized by serum thyroid-stimulating hormone (TSH) levels that are above the reference range, while the serum total or free thyroid hormone levels remain within the reference range (1). The prevalence of SCH ranges between 4 and 20% of the population in different regions of the world (2). In recent years, a growing body of evidence has indicated that SCH is an independent risk factor for lipid metabolic disorders, such as cardiovascular diseases and nonalcoholic fatty liver disease (NAFLD) (3). Although there have been studies on the SCH molecular mechanism, mainly focusing on ligand-receptor interactions and the biological effects at the cellular or molecular levels (4), the underlying mechanism of this condition currently remains unclear.

MicroRNAs (miRNAs/miRs) are small non-coding RNAs with a length of ~18-23 nucleotides, which interact with mRNAs upon specific base-pairing in the 3'-untranslated region to repress the mRNA expression via translational inhibition or mRNA degradation. miRNAs repress multiple target genes in linear whole pathways or network nodes, thereby simultaneously exerting a larger cumulative effect (5). These small molecules are the focus of basic research on regulating biological processes, as well as of applied research for their potential application as biomarkers and therapeutic agents (6). Recently, accumulating evidence has supported the importance of hepatic miRNAs in the physiological process.
of hepatic lipid metabolism and a wide spectrum of diseases, including viral hepatitis, cirrhosis, hepatoma and NAFLD (7). However, little is known on the role of miRNAs in hepatic lipid metabolic disorders associated with SCH.

Proteomics analysis has been widely used to identify and quantify proteins associated with biological functions that are regulated by miRNAs (8). miRNA target regulatory modules have previously been identified and studied in liver fibrosis (9). However, to the best of our knowledge, no previous study has investigated the regulatory modules in SCH. In the present study, miRNAs alterations and proteome profiles in SCH were compared and integrated. in SCH mice. The integration was achieved by targeting predictions at the sequence level.

Materials and methods

Research animals. Male C57BL/6 mice (age, 7 weeks, weight, 20-21 g) were purchased from Vital River Corporation (Beijing, China) and housed in designated specific-pathogen-free cages on a 12 h light–dark cycle at 23°C and 60% humidity. Mice were allowed free access to an irradiated chow and sterilized water. After acclimatization for 1 week, the mice were randomly divided into two groups, including the SCH model (n=9) and control (CON, n=7) groups. The SCH and CON groups were given methimazole (MMI; 0.08 mg/kg body weight per day) or an equal volume of vehicle, respectively, in their drinking water for 16 weeks. Finally, the mice were euthanized using pentobarbital sodium (concentration=20 mg/ml; dose=120 mg/kg body weight) through the intraperitoneal route. Following cervical dislocation to ensure death, 600 µl blood samples and the liver tissues of mice were collected. All animal experiments were performed according to the relevant guidelines and institutional policies (10). The animal protocol was approved by the Shandong Provincial Hospital Animal Care and Use Committee (no. 2015-003; Jinan, China).

Serum TSH, free thyroxine (FT4), lipid profile and liver function assay. Serum TSH level was determined using a mouse ELISA kit (MyBioSource), following the product manual. Serum FT4 concentrations were determined using specific radioimmunoassay kits (Jiuding Diagnostic). Serum triglyceride (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), alanine transaminase (ALT) and aspartate aminotransferase (AST) levels were analyzed by LC-MS/MS, according to a previously described protocol (13). The mRNA extraction, reverse transcription (RT) into cDNA and quantitative polymerase chain reaction (qPCR) for miRNA. Liver miRNAs were extracted from the tissues using the MiRcute miRNA isolation kit (Tiangen Biotech Co., Ltd.), according to the manufacturer's protocol. Next, the concentration of RNA was quantified using a NanoDrop 1000 system (Nanodrop Technologies; Thermo Fisher Scientific, Inc.). The cycle quantification (Cq) value was calculated using the second derivative maximum method (11). U6 small nuclear RNA was used as the internal control. The relative expression of each miRNA following normalization was determined as follows: Cq (U6)-Cq (miRNA).

Protein preparation and liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis. Hepatic protein was extracted as previously described (12). Next, protein concentration was determined using the BCA Assay kit (Thermo Fisher Scientific, Inc.). The protein samples from three mice were pooled with the ratio 1:1:1 as a biological sample to avoid erroneous conclusions due to individual variations. Each pool was analyzed in duplicate. A total of 200 µg protein from each pool was reduced, alkylated and digested with trypsin. Subsequently, the dried peptides were labeled following the manufacturer's recommendations of the isobaric tags for relative and absolute quantitation (iTRAQ) 4-plex kits (SCIEX, Framingham, MA, USA) with iTRAQ tags, as follows: iTRAQ 114 for CON, iTRAQ 115 for SCH, iTRAQ 116 for CON replicate and iTRAQ 117 for SCH replicate. The eluted peptides were analyzed by LC-MS/MS, according to a previously described protocol (13).

Functional enrichment analysis. For functional analysis of the altered proteins, the proteins were imported into the Database for Annotation, Visualization and Integrated Discovery (DAVID version 6.7; http://david.abcc.ncifcrf.gov/) which involves an integrated biological knowledge base and
analytical tools designed to systematically extract biological meaning from large gene/protein lists in order to perform a Gene Ontology (GO) functional enrichment analysis and a Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis. Path mining tools such as gene function classification, functional annotation table or clustering were used for analysis. Furthermore, TargetScan (Release 7.2; http://www.targetscan.org/vert_72/) and miRanda (August 2010 release; http://www.microrna.org/microrna/microrna/home.do) database analyses were employed to identify putative targets of miRNAs among the differentially expressed proteins (14).

Statistical analysis. The data were analyzed using SPSS software (version 23.0; IBM Corp.) and are expressed as the mean ± standard deviation. Differences between two groups were compared using an unpaired Student's t-test. Cluster version 3.0 and Java TreeView version 1.60 (Stanford University) were used to perform agglomerative hierarchical cluster analysis. All of the calculated P-values were two-sided, and P<0.05 was considered to indicate a statistically significant difference.

Results

Generation of an SCH mouse model and determination of lipid parameters. An SCH mouse model was established by MMI administration for 16 weeks. The SCH mice exhibited normal serum FT4 levels (Fig. 1A) and higher TSH levels (Fig. 1B) as compared with those in CON mice. The serum ALT (Fig. 1C) and AST (Fig. 1D) levels in SCH mice were similar to those exhibited by the CON group. In addition, serum TG (Fig. 1E), TC (Fig. 1F) and LDL-C (Fig. 1G) levels in SCH mice were all significantly higher when compared with those in CON mice, whereas there was no marked difference in serum HDL-C levels (Fig. 1H). Oil red O staining of liver tissues indicated greater lipid droplet accumulation in the livers of SCH mice in comparison with the CON mice (Fig. 1I). Furthermore, the hepatic TG (Fig. 1J) and TC (Fig. 1K) content were markedly increased in the SCH mice.

Differentially expressed miRNAs in the livers of SCH mice. 17 candidate miRNAs involved in hepatic lipid metabolic were selected based on previous studies (15-32) and non-coding RNA sequencing (data not shown). The present study then screened these miRNAs by RT-qPCR. Among these 17 miRNAs, 8 miRNAs were found to be significantly dysregulated in SCH mice, including mmu-miR-10b-5p, mmu-miR-24-3p, mmu-miR-29a-3p, mmu-miR-30b-5p, mmu-miR-34a-5p, mmu-miR-125b-5p, mmu-miR-130a-3p and mmu-miR-199a-5p (Fig. 2A; P<0.05). The expression of the remaining 9 miRNAs was not markedly different between the SCH and CON mice (Fig. 2B). These results suggested that the 8 dysregulated miRNAs may be involved in the development of hepatic lipid metabolic disorders in SCH.

Functional analysis of proteins identified by proteomics. The present study performed iTRAQ-based proteomic analysis in the livers of SCH mice. 17 candidate miRNAs involved in hepatic lipid metabolic were selected based on previous studies (15-32) and non-coding RNA sequencing (data not shown). The present study then screened these miRNAs by RT-qPCR. Among these 17 miRNAs, 8 miRNAs were found to be significantly dysregulated in SCH mice, including mmu-miR-10b-5p, mmu-miR-24-3p, mmu-miR-29a-3p, mmu-miR-30b-5p, mmu-miR-34a-5p, mmu-miR-125b-5p, mmu-miR-130a-5p and mmu-miR-199a-5p (Fig. 2A; P<0.05). The expression of the remaining 9 miRNAs was not markedly different between the SCH and CON mice (Fig. 2B). These results suggested that the 8 dysregulated miRNAs may be involved in the development of hepatic lipid metabolic disorders in SCH.
the differentially expressed proteins were further categorized by DAVID analysis.

By GO functional classification, the identified proteins were clustered into three groups, including proteins involved in biological processes, cell components and molecular functions. In the biological process cluster, the majority of proteins were assigned to ‘metabolic process’ (38%) and ‘cellular process’ (28%; Fig. 3A). The top two enriched terms in the cellular component cluster included ‘cell part’ (44%) and ‘organelle’ (20%; Fig. 3B). In the molecular function cluster, a
Figure 2. Differentially expressed miRNAs in the livers of SCH mice. (A) A total of 8 miRNAs were downregulated and (B) A total of 9 miRNAs were not markedly changed in the livers of SCH mice. U6 snRNA was used as the internal control. The horizontal lines represent the mean. Statistical significance was assessed using Student's t-test. The data are presented as the mean ± standard deviation. *P<0.05 and **P<0.01 vs. CON group (n=7). miRNA, microRNA; SCH, subclinical hypothyroidism; CON, control.
Figure 3. Functional analysis of proteins identified by proteomics. Percentages of proteins enriched in different (A) biological processes, (B) cellular components and (C) molecular functions, according to Gene Ontology enrichment analysis. (D) Results of KEGG pathway analysis. The vertical axis denotes the KEGG pathway categories, and the horizontal axis denotes the negative logarithmic P-value (-log_{10} P-value), indicating the statistical significance of the pathways based on DAVID analysis. KEGG, Kyoto Encyclopedia of Genes and Genomes.
Great number of proteins were assigned to ‘catalytic activity’ (58%) and ‘binding’ (24%; Fig. 3C). Furthermore, according to KEGG pathway analysis, the majority of the identified proteins were involved in KEGG pathways such as ‘Alzheimer’s disease’, ‘oxidative phosphorylation’, ‘Parkinson’s disease’ and ‘NAFLD’ (Fig. 3D). Taken together, the results suggested that these differentially expressed proteins may be important effectors associated with hepatic lipid metabolic disorders in SCH.

Hierarchical clustering based on the 17 candidate miRNAs and 36 proteins. Hierarchical clustering was performed based on the 17 candidate hepatic miRNAs (Fig. 4A). Of the 7 CON mice, 6 were clustered together with 2 SCH mice. Of the 9 SCH mice, 7 were clustered together with only 1 CON mouse. Next, a hierarchical cluster was constructed using the expression values of the 36 identified proteins (Fig. 4B). The two groups exhibited marked separation, indicating that the liver proteins expressed in SCH mice were distinct from those in CON mice.

To investigate the correlation between altered miRNAs and proteins in the livers of SCH mice, the present study established a module between miRNAs and proteins using TargetScan and miRanda for prediction (Table II). The regulatory module contained 3 miRNAs, 4 proteins and 4 miRNA-protein connections. It was observed that miR-34a-5p targets thioredoxin (Txn), miR-130a-3p targets elongation factor 1-beta (Eef1b) and prosaposin (Psap), while miR-24-5p targets selenium-binding protein 2 (Selenbp2).

Discussion

In previous clinical studies, a positive association has been reported between TSH and serum TG levels (33). TG synthesis could be induced by TSH through GPAT3 in adipocytes (34), while TSH has been demonstrated to promote hepatic TG accumulation by increasing SREBP-1c activity (12). In order to further investigate the effect of TSH on hepatic lipid metabolism, a noninvasive method of MMI administration in the drinking water to successfully establish SCH mouse...
Table II. Targets of differentially expressed miRNAs in subclinical hypothyroidism mice.

<table>
<thead>
<tr>
<th>miRNA</th>
<th>Putative target gene</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>mmu-miR-24-3p</td>
<td>Selenbp2</td>
<td>Selenium-binding protein 2</td>
</tr>
<tr>
<td>mmu-miR-34a-5p</td>
<td>Txn</td>
<td>Thioredoxin</td>
</tr>
<tr>
<td>mmu-miR-130a-3p</td>
<td>Eef1b</td>
<td>Elongation factor 1-β</td>
</tr>
<tr>
<td></td>
<td>Psap</td>
<td>Prosaposin</td>
</tr>
</tbody>
</table>

miRNA/miR, microRNA.

model (4). miRNAs have been studied in a variety of liver diseases, including viral hepatitis, cirrhosis, hepatoma and NAFLD (7,35). However, their application is challenging, as miRNAs have different and intersecting target genes (5). Previous research has revealed that modules containing genes and targeting regulators could be used as diagnostic and therapeutic tools (36). Therefore, it was hypothesized that miRNA and proteome profiles could be integrated to form an miRNA-protein regulatory module, which may be associated with hepatic lipid metabolism disorders in SCH and thereby be used to explore potential therapeutic targets.

In the present study, a total of 17 hepatic miRNAs that have been confirmed as crucial gene regulators of hepatic lipid metabolism were selected to explore their profiles in SCH, among them, miR-10b regulates hepatocyte steatosis by targeting peroxisome proliferator-activated receptor-α (15). In addition, miR-24 and miR-125b regulate hepatic lipid accumulation by targeting insulin-induced gene 1 and fatty acid synthase (FAS), respectively (16,20). miR-29 and miR-486 are reported to regulate cholesterol metabolism by targeting hydroxy-3-methyl-glutaryl-CoA reductase and histone acetyltransferase-1, respectively (17,28). Furthermore, miR-30b-5p and miR-30c-5p belong to the same family of miRNAs regulating fatty acid synthesis genes, targeting elongation of very long chain fatty acids protein 5 (ELOVL5) and fatty acid synthase (FAS), respectively (18,19). miR-34a has been reported to participate in proinflammatory NAFLD (24), while miR-130a-3p directly targets transforming growth factor-β receptors 1 and 2, which may contribute to hepatic fibrosis (21). Additionally, miR-148a regulates cholesterol and TG homeostasis by controlling multiple metabolic regulatory circuits (30). miR-155 and miR-467b modulate hepatic steatosis by targeting liver X receptor α and hepatic lipoprotein lipase (22,23). It has also been demonstrated that miR-199a-5p and miR-370 were implicated in fatty acid β-oxidation in mitochondria (25,27). In addition, by simultaneously regulating insulin signaling and adipogenesis, miR-206 reduced lipid and glucose production in the liver of obese mice (29). In liver, miR-29bc-3p promotes lipogenesis by suppressing AMPKα1 expression and activity (31). Hepatic miR-210 is elevated in cholestatic mice and PBC patients, promoting bile acids-induced liver injury by targeting mixed-lineage leukemia-4 (MLL4) (32). In the present study, it was observed that 8 (miR-10b-5p, miR-24-3p, miR-29a-3p, miR-30b-5p, miR-34a-5p, miR-125b-5p, miR-130a-5p and miR-199a-5p) out of these 17 miRNAs associated with hepatic lipid metabolic disorders were downregulated in the livers of SCH mice, suggesting that these miRNAs may be involved in hepatic lipid metabolic disorders in SCH.

The present study subsequently conducted iTRAQ labeling analysis and identified 36 proteins with altered expression levels. Targeting predictions of miRNAs by TargetScan and miRanda were used to identify the potential targets (37). Of the significantly altered proteins, four were found to be potential targets of 3 differentially expressed miRNAs, namely the Txn, Eef1b, Psap and Selenbp2 proteins. It has been reported that the the Txn protein, has notable properties as a crucial defense against oxidative stress (38). Txn forms a system with thioredoxin reductase and nicotinamide adenine dinucleotide phosphate, and further eliminates reactive oxygen species, the excessive production of which leads to oxidative stress contributing to cardiac dysfunction and insulin resistance in NAFLD (39). TSH is known to directly produce oxidative stress, and oxidative damage to lipid peroxidation has been reported in SCH patients (40). The present study demonstrated marked alterations in miR-34a-5p and Txn levels in SCH mice, which may be involved in the development of hepatic lipid metabolism disorders in these mice via oxidative stress.

Eef1b, an enzyme that may be localized in the endoplasmic reticulum, has been reported to promote protein synthesis, and protect Leishmania major from chemical and oxidative stress (41). Furthermore, it is known that oxidative damage leads to lipid peroxidation, which is a key component of SCH and NAFLD (42). Thus, Eef1b, as the target of miR-130a-3p, may be involved in hepatic lipid metabolism disorders in SCH mice through lipid peroxidation.

Several minerals and trace elements are essential for normal thyroid hormone metabolism, such as iodine, iron and selenium, and hypothyroidism can easily arise in regions of severe iodine and selenium deficiency (43). However, to the best of our knowledge, the roles of Selenbp2 and Psap in hepatic lipid metabolism in SCH have not yet been studied; thus, the underlying mechanism requires further exploration.

In conclusion, the present study identified a miRNA-protein regulatory module, which included 3 miRNAs and 4 proteins, that may be associated with hepatic lipid metabolism by integrating miRNA and proteome profiles in SCH mice. To the best of our knowledge, no previous studies have investigated miRNAs that are involved in hepatic lipid metabolism in SCH, and the present study may thus provide potential therapeutic targets and significant evidence for researchers to better understand the underlying pathogenesis of hepatic lipid metabolism in SCH. However, further investigation will be necessary in the future to verify these findings.

Acknowledgements

The abstract of this study was presented at the Endocrine Society Annual Meeting ENDO 2019, 22-23rd March 2019, New Orleans, LA, USA and was published as abstract number SAT-047.
Funding
This study was supported by grants from the National Key Research and Development Program of China (no. 2017YFC1309800), the National Basic Research Program (no. 2012CB524900), the National Natural Science Foundation (nos. 81230018, 81471006, 81430020 and 81500595) and the Taishan Scholar’s Special Expert Plan.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions
LZ performed the animal experiments and wrote the draft of the manuscript. KW, TB and LZ performed the molecular biology experiments. LG helped to develop the manuscript and interpreted the results. XZ and WC designed the study and performed data analysis. All authors approved the final manuscript for publication.

Ethics approval and consent to participate
All animal experiment procedures were approved by the Shandong Provincial Hospital Animal Care and Use Committee (approval no. 2015-003) and were in compliance with the Guide for the Care and Use of Laboratory Animals.

Patient consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

References
1. Surks MI, Ortiz E, Daniels GH, Sawin CT, Col NF, Cobin RH, Franklin JA, Hershman JM, Burman KD, Denke MA, et al: Subclinical thyroid disease: Scientific review and guidelines for diagnosis and management. JAMA 291: 228-238, 2004.